← Back to all trials
Recruiting
NCT07516769
Nicorandil as Anti-inflammatory in Rheumatoid Arthritis
Conditions: Rhumatoid Arthisis
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 46
Sponsor: Tanta University
Location: Tanta university Tanta Gharbia Governorate
Summary
This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.
Eligibility Criteria
Inclusion Criteria:
* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) i.e., 28 joints disease activity score (DAS-28) \>2.6.
* Patients receiving the conventional DMARDs
Exclusion Criteria:
* Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.
* Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.
* Patients receiving oral prednisolone greater than 15mg/day.
* Patients with hypersensitivity to study medications.
* Patients using antioxidants.
* Pregnant and lactating females.
Source: ClinicalTrials.gov (NCT07516769). StuddyBuddy aggregates publicly available trial information.
